Abstract 15674: Cardiovascular Manifestation and Its Association With In-hospital Outcome in Patients Admitted in Intensive Care With Covid19: Middle Eastern Country Multicenter Data

Fahad Alkindi, khamis alhashmi, Salma Alharthi, khalid alsaidi, shabib alasmi, Tasneem Alrashdi, Huda Alkhalili, Feryal Khamis, Adil Algafri, Sultan Allawati, muzna alfarsi, Sathiya Murthi, Mujahid Al busaidi, Abdullah balkhair, Hafidh Alhadi, khalid Alrasadi, Hilal Alsabti

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The world has experienced an outbreak of coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The middle east countries were hit like the rest of the world with this pandemic. Hypothesis: In-hospital mortality has been reported in many countries, but similar reports from middle eastern countries have not been well described. Methods: In this retrospective, multicentre cohort study, we included all adult hospitalized in the intensive care Unit with laboratory-confirmed COVID-19 in the two main hospitals in Oman, Sultan Qaboos University Hospital SQUH and Royal Hospital RH between the period of 1 st of March to May 30 th , 2020. Demographic, clinical presentation, treatment and outcome, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings: 153 patients admitted in ICU ,60 from SQUH and 93 from RH were included in this study, of whom 131 (85.6%) were discharged and 22 (14.3%) died in hospital. The mean age of the patients was 49.56±15.20. Males were accounted 126 (83.4%) and females were 25 (16.6%). Nearly 40% of them were Omani citizens and rest of 60% were residents of Oman. Those who have history of coronary artery disease found to have higher in hospital mortality rate OR= 4.09, 95% C.I 1.57-10.6) in which mortality in patients on aspirin was (31.8% in non-survival group vs 10.8% in survival group, p=0.047), clopedogril (18.2% vs 2.3%, p=0.009) and statin (31.8% vs 10.6%, p=0.016)At presentation, non-survivals were found to have significantly higher troponin with the risk of 7.07 (C.I. 2.09-23.92. p=0.002). In fact, patients with high sensitivity troponin rise >100 ng/L were more likely to die 5.83 times than the group with troponin 100ng/L was independent risk factors for death of COVID-19. Identifying these risk factors could help to assess the prognosis of these patients at early stage.
Original languageEnglish
JournalCirculation
Volume142
Issue numberSuppl_3
DOIs
Publication statusPublished - Nov 17 2020

Cite this